The main business of Xinhexin Biopharmaceutical includes the research and development, production and sales of steroid drug intermediates and APIs, as well as the import and export of related products. It is the first enterprise in China that uses phytosterol as the starting material to prepare steroid hormone drug intermediates and APIs and realize industrialized production. high-tech enterprises. The company recently received a new round of investment of 198.074128 million yuan. The investors include Hunan Jiukang Venture Capital Partnership (Limited Partnership), Changsha Lugu Capital Management Co., Ltd., Hunan Bofu Cultural Industry Investment Fund Enterprise (Limited Partnership), Changsha Shangshan Xinfu Venture Capital Partnership (Limited Partnership), Shenzhen Hongdian Shengshi Pharmaceutical Investment Partnership (Limited Partnership), Hangzhou Xiaochi Feihong Venture Capital Partnership (Limited Partnership), Hunan Bofu Yueying Enterprise Management Partnership (Limited Partnership), etc.
This article is reproduced from: https://www.itjuzi.com/investevent/13302550
This site is for inclusion only, and the copyright belongs to the original author.